Aquestive Therapeutics vs Biofrontera
Aquestive Therapeutics and Biofrontera are similar in size: $44.5m and $41.7m of revenue in their latest fiscal years. Biofrontera grew faster (11.7% against -22.6%). Biofrontera kept more of each dollar of sales as profit: a net margin of -25.3% against -188.1%.
| Latest fiscal year | Aquestive TherapeuticsAQST, 2025 | BiofronteraBFRI, 2025 |
|---|---|---|
| Revenue | $44.5m | $41.7m |
| Revenue growth | -22.6% | 11.7% |
| Net income | −$83.8m | −$10.5m |
| Operating margin | -159.5% | — |
| Net margin | -188.1% | -25.3% |
| Return on equity | — | -141.3% |
| Free cash flow | −$53.0m | −$13.4m |
| Cash | $121m | $6.4m |
| Total debt | $55.0m | $0 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 147 | 92 |
| Market value | $485m | $12.5m |
| Price vs our value range | — | — |
| Moat score | 24 (Weak) | — |
| Insider trades, 12 months | 0 buys, 16 sales | 0 buys, 0 sales |